Chimerix (CMRX) Sees Strong Trading Volume
Shares of Chimerix Inc (NASDAQ:CMRX) saw unusually-high trading volume on Tuesday . Approximately 4,337,647 shares were traded during mid-day trading, an increase of 849% from the previous session’s volume of 457,271 shares.The stock last traded at $2.74 and had previously closed at $2.09.
CMRX has been the topic of several recent research reports. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a report on Friday, February 22nd. HC Wainwright restated a “buy” rating on shares of Chimerix in a report on Wednesday, February 6th. ValuEngine raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Citigroup decreased their target price on shares of Chimerix from $4.25 to $2.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 6th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Chimerix currently has a consensus rating of “Hold” and an average target price of $5.06.
The stock has a market cap of $104.35 million, a PE ratio of -1.92 and a beta of 1.34.
Hedge funds have recently bought and sold shares of the stock. Deutsche Bank AG boosted its stake in shares of Chimerix by 27.7% in the fourth quarter. Deutsche Bank AG now owns 258,033 shares of the biopharmaceutical company’s stock valued at $662,000 after purchasing an additional 55,950 shares during the period. Geode Capital Management LLC increased its stake in shares of Chimerix by 21.6% during the fourth quarter. Geode Capital Management LLC now owns 645,273 shares of the biopharmaceutical company’s stock valued at $1,658,000 after acquiring an additional 114,702 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Chimerix by 2.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,871 shares of the biopharmaceutical company’s stock valued at $6,715,000 after acquiring an additional 56,347 shares during the period. HRT Financial LLC acquired a new stake in Chimerix in the fourth quarter worth approximately $40,000. Finally, 683 Capital Management LLC bought a new position in Chimerix during the 4th quarter valued at $771,000. Hedge funds and other institutional investors own 73.39% of the company’s stock.
About Chimerix (NASDAQ:CMRX)
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Further Reading: Call Option Volume
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.